Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after ...

Plus, pharmacy groups famed for opioid bankruptcies join forces and the mysterious Deutsche Bank employee making more than its CEO ...

The pairing of Mallinckrodt plc and Endo Inc. is expected to create a pharma heavyweight that will generate $3.6 billion in 2025 revenue after the duo combines their generic pharmaceuticals businesses ...

The U.S. Food and Drug Administration on Thursday made recommendations to vaccine manufacturers for the virus strains to be ...

The Mallinckrodt-Endo combination will have approximately 5,700 employees at closing, as well as 17 manufacturing facilities, 30 distribution centers, and an operating footprint primarily located in ...

Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.

The two companies are merging after previously filing for bankruptcy due to opioid-related litigation and financial losses.

Mallinckrodt and Endo, drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced ...

Wilmington, Delaware-- (Newsfile Corp. - March 13, 2025) - Rigrodsky Law, P.A. is investigating Endo, Inc. ("Endo") (OTC: NDOI) regarding possible breaches of fiduciary duties and other violations of ...

Mallinckrodt and Endo are merging in a $6.7 billion deal, with a pro forma NYSE listing and $900 million in financing.

Dodig will remain on board as special adviser to incoming CEO Harry Culham and the board until April 30, 2026. Culiham is to take the CEO position on Nov. 1. An arbitrator ruled that a former Meta ...

Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York ...